Possis Perma-Flow Artificial Coronary Graft Gains HDE Approval
This article was originally published in The Gray Sheet
Executive Summary
U.S. launch of Possis Medical's Perma-Flow coronary bypass graft is being delayed pending an analysis of the company's strategic business plan by Solomon Smith Barney. On May 4, Possis announced receipt of a humanitarian device exemption from FDA.